Datta S, Chatterjee K, Wiley R (2010) Decreasing abnormal nocifensive responses in the bilateral chronic constriction injury (bCCI) model of neuropathic pain: Effects of lumbar intrathecal CCK-saporin. Neuroscience 2010 Abstracts 175.22/MM12. Society for Neuroscience, San Diego, CA.
Summary: The bCCI model produces long lasting -cold hyperalgesia (at least 100 days) along with decreases in staining for cholecystokinin (CCK) in the dorsal horn (DH). Spinal cholecystokinin (CCK) has anti-opiate activity, and selective destruction of DH neurons expressing CCK receptors by injection of intrathecal CCK-saporin, in naïve rats decreases thermal nocifensive reflex responses and is additive with morphine in decreasing nocifensive responses to heat. In the present study, we sought to determine the effects of intrathecal CCK-sap in the bCCI model of neuropathic pain in Long Evans female rats. bCCI rats underwent bilateral ligation of the sciatic nerves with chromic gut sutures. Controls underwent sham surgery with no ligation. Rats were tested on 0.3 C cold plate, thermal preference task (TPT) (shuttle box with floor temperatures of 15 C vs 45 C) and mechanical stimulation (von Frey). bCCI produced increased responses on the cold plate. 21 days after the bCCI surgery, the rats were injected with 1500 ng CCK-sap into the lumber CSF. Then, thermal and mechanical testing was repeated at intervals. Intrathecal CCK-sap injections decreased abnormal nocifensive responding of bCCI rats on the cold plate. CCK-sap reduced withdrawal responses to mechanical stimulation in bCCI rats. In TPT testing, the bCCI animals were hyperalgesic to cold (reduced cold side occupancy). After intrathecal CCK-sap injections, thermal preference was reversed (increased cold side occupancy). We interpret these results as showing that CCK-sap reverses abnormal nocifensive responses of bCCI in rats to aversive cold and mechanical stimuli. These results suggest that silencing CCK receptor-expressing superficial DH neurons is a potential strategy for development of new treatments for chronic neuropathic pain.
Related Products: CCK-SAP (Cat. #IT-31)